Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C24H27N5O2
CAS Number:
Molecular Weight:
417.50
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
SMILES string
N5(CCC(CC5)N)c1c2nc(ccc2ccc1)[n]3c4c(nc3)cc(cc4)OCCOC
InChI
1S/C24H27N5O2/c1-30-13-14-31-19-6-7-21-20(15-19)26-16-29(21)23-8-5-17-3-2-4-22(24(17)27-23)28-11-9-18(25)10-12-28/h2-8,15-16,18H,9-14,25H2,1H3
InChI key
DEEOXSOLTLIWMG-UHFFFAOYSA-N
assay
≥95% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
−20°C
Quality Level
Related Categories
Biochem/physiol Actions
ATP-competitive, potent and selective platelet-derived growth factor receptor (PDGFR) inhibitor against tumor growths in vivo.
CP-673451 is an ATP-competitive, potent and selective platelet-derived growth factor receptor inhibitor (PDGFR1 (β)/PDGFR2 (α) IC50 = 1/10 nM with 10 μM ATP; IC50 = 252 nM/c-kit, 450 nM/VEGFR-1/2; >450-fold reduced potency toward other angiogenic receptors and non-receptor kinases). CP-673451 potently inhibits PDGF-BB-induced receptor phosphorylation (IC50 = 6.4 nM; PDGFR1 transfectant) and effectively suppress human cancer xenografts-derived tumor in mice in vivo (ED50 ≤33 mg/kg via b.i.d. or q.d. p.o.) by inhibiting PDGFR phosphorylation and angiogenesis in tumor tissues.
Storage Class
11 - Combustible Solids
wgk
WGK 3
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
W Gregory Roberts et al.
Cancer research, 65(3), 957-966 (2005-02-12)
CP-673,451 is a potent inhibitor of platelet-derived growth factor beta-receptor (PDGFR-beta) kinase- and PDGF-BB-stimulated autophosphorylation of PDGFR-beta in cells (IC(50) = 1 nmol/L) being more than 450-fold selective for PDGFR-beta versus other angiogenic receptors (e.g., vascular endothelial growth factor receptor
Lu Yang et al.
Cell death and differentiation, 27(7), 2066-2080 (2020-01-24)
Lack of insight into the identity of the cells that initiate metastasis hampers the development of antimetastatic therapies. Only a tiny fraction of tumor cells termed metastasis-initiating cells (MICs) are able to successfully seed metastases, causing recurrence and therapeutic resistance.
Yuling Xi et al.
OncoTargets and therapy, 7, 1215-1221 (2014-07-23)
Lung cancer is the leading cause of cancer mortality in the world. Although some advances in lung cancer therapy have been made, patient survival is still poor. The platelet-derived growth factor receptors (PDGFRs) and their ligands play critical roles in
Feng He et al.
Journal of hepatology, 72(6), 1182-1195 (2020-02-28)
Hepatomegaly can be triggered by insulin and insulin-unrelated etiologies. Insulin acts via AKT, but how other challenges cause hepatomegaly is unknown. Since many hepatomegaly-inducing toxicants and stressors activate NRF2, we examined the effect of NRF2 activation on liver size and
Shuguang Pan et al.
American journal of translational research, 12(7), 3577-3595 (2020-08-11)
Cholangiocarcinoma (CCA) is an aggressive tumour with a poor prognosis due to its late clinical presentation and the lack of effective non-surgical therapies. Previous studies have reported that platelets are implicated in tumour invasion and metastasis, while their role and
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service